tbuckley/cabot-search huggingface dataset:
Anleitung zur Vornahme von Leichenöffnungen
Authors: R. Maresch, H. Chiari
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fluoroscopy-guided endoscopic recanalization of an obstructed gastroesophageal junction in a child
Authors: Saverio Armellini, Daniel Moribe, Joao Seda, Paulo Chapchap, Rubens Sallun, Marco D’Assuncao
Journal: Endoscopy (2015)

There are various conditions that can lead to complete obstruction of the esophagus, with possible causes including radiotherapy, ingestion of caustic agents, foreign bodies, peptic esophagitis, and iatrogenic factors. In most situations, major surgical intervention is required to restore the patency of the alimentary tract. Standard endoscopic dilation is not possible because no lumen exists [1] [2]. The presence of a gastrostomy tube may allow for a combined endoscopic and fluoroscopic approach as demonstrated by the following technique.
Abstract 2647: Predictors of Resuscitation in a Swine Model of VF Cardiac Arrest: Superiority of Amplitude Spectral Area (AMSA) to Predict a Return of Spontaneous Circulation When Resuscitation Efforts Are Prolonged
Authors: Julia Indik, Daniel Allen, Madhan Shanmugasundaram, Karl B Kern, Ronald W Hilwig, Robert A Berg
Journal: Circulation (2009)
Abstract 15398: Symptoms of Insomnia are Associated with Reduced Endothelial Function
Authors: Faye S Routledge, Sandra B Dunbar, Ann E Rogers, Octavian C Ioachimescu, Kristina Euwer, Danny Eapen, Arshed A Quyyumi
Journal: Circulation (2012)

Background: Recent studies link insomnia with increased risk of hypertension, myocardial infarction, and mortality. Endothelial function may be a mechanism by which insomnia affects cardiovascular ...
The Man Who Lived for Tomorrow: A Biography of William Hallock Park, M.D.
Authors: Wade Wright Oliver
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2516: Primary Aldosteronism And Inappropriateness Of Left Ventricular Mass
Authors: Maria Lorenza Muiesan, Massimo Salvetti, Anna Paini, Claudia Agabiti Rosei, Cristina Monteduro, Gloria Galbassini, Eugenia Belotti, Carlo Aggiusti, Linda Micheletti, Valentina Paderno, Enrico Agabiti Rosei
Journal: Circulation (2007)

Background: The calculation of values of left ventricular mass (LVM) exceeding individual needs to compensate haemodynamic load (inappropriate LVM) can identify patients with high CV risk (de Simone J. Hypertens 2001, Muiesan Hypertens 2007). However, a substantial percentage of LVM variance remains unexplained, even when the influence of cardiac workload, of the body size and gender are taken into account. It is possibile that other factors, non hemodynamic (genetic) or neurohumoral (renin-angiotensin-aldosterone system) may explain the individual LVM. Aim of this study to evaluate the prevalence of inappropriate LVM (iLVM) in patients with primary aldosteronism (PA). Methods 94 PA (51 with adrenal hyperplasia and 43 with adrenal adenoma), (age 49 ± 11 years, 41 F) and in 94 essential hypertensives (EHT) matched for age and sex, underwent echocardiography. The appropriateness of LVM to cardiac workload was calculated by the ratio of observed LVM to the value predicted for an individual gender, height, and stroke work at rest, from a reference population (de Simone et al, 1998). All subjects underwent laboratory examinations, including PRA and plasma aldosterone, and clinic and 24 hours blood pressure measurement. Results No significant differences were observed for clinic and 24 hours BP, clinic and 24 hours heart rate, glucose and lipids between PA and EHT. The prevalence of traditionally defined LV hypertrophy (LVMI ≥ 47 g/m 2.7 in F and 50g/m 2.7 in M) was greater in PA patients than in EHT (48 vs 19 % chi 2 = 0.02). In patients without LVH, the prevalence of iLVM (&gt; 128% of predicted) was also greater in patients with PA than in EHT controls, (14 % vs 2.5 %, chi 2 p = 0.012). Among PA those with iLVM had a higher BMI, increased uric acid, lower midwall fractional shortening, and prolonged isovolumic relaxation time (p &lt; 0.05 at least). In all patients a small, albeit statistically significant, correlation was observed between the Aldosterone/PRA levels and the ratio of observed/predicted LVM (r = 0.18, p &lt; 0.02). Conclusions: In patients with PA the prevalence of iLVM is increased, even in the absence of traditionally defined LVH. The increase in aldosterone levels could contribute to the increase of LV mass exceeding the amount needed to compensate hemodynamic load.
Two memorable patients: Matthew and Adam
Authors: A. K Webb
Journal: BMJ (2000)

When I first looked after Matthew and Adam they reminded me of the twins who knew each other's thoughts in On The Black Hill by Bruce Chatwin. They would sit in the corner of the physiotherapy room not talking but communicating and were totally content with each other's company.

Matthew and Adam were not twins. Matthew was the younger brother by two years, but they both shared the same potentially lethal disease—cystic fibrosis. They both had a total commitment to Manchester City Football Club and a total dislike of Manchester United.

Their parents had been told that they would die in childhood, but they survived into adolescence and then into their 20s. Sharing the same disease and interests brought them into continuous close contact. They both started to work as sports journalists and were successful. …
The Croonian Lectures on the Psychology of the Special Senses and Their Functional Disorders Delivered Before the Royal College of Physicians in June, 1920.
Authors: Arthur Frederick Hurst
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).
Authors: W. J. Gradishar, F. Dalenc, V. G. Kaklamani, F. Costa, T. P. Sahoo, J. Segalla, D. Lokanatha, H. Pinczowski, V. Raina, J. Baselga
Journal: Journal of Clinical Oncology (2010)

1073 Background: Two phase IIb trials in pts with advanced BC demonstrated activity for SOR plus standard chemotherapy for the primary endpoint of PFS. In Study A, median PFS for SOR + capecitabine (CAP) versus PL+CAP was 6.4 versus 4.1 mo (hazard ratio [HR] 0.58; 1-sided p=0.0006). In Study B, median PFS for SOR + paclitaxel (PAC) versus PL+PAC was 6.9 versus 5.6 mo (HR 0.79; 1-sided p=0.09). In both studies, randomization was stratified by visceral status with slight imbalances in some covariates. We performed MVA to assess the impact of imbalances and prognostic factors on PFS. Methods: Study A: Pts (N=229) with ≤1 prior chemo regimen for advanced BC were randomized to CAP (1,000 mg/m2 po, twice daily [BID], 14 of 21 days) + SOR (400 mg po, BID) or PL. Study B: Pts (N=237) with no prior chemo for advanced BC were randomized to PAC (90 mg/m2/wk IV, 3 wk on/1 wk off) + SOR (400 mg po, BID) or PL. MVA: Cox proportional hazards models of PFS stratified by visceral status were used for each study. Additional covariates were selected based on degree of imbalance between study arms and prognostic importance and retained if 1-sided p <0.15. Results: After adjusting for covariates, SOR+CAP was associated with a 36% risk reduction vs PL+CAP in Study A, and SOR+PAC with a 27% risk reduction vs PL+PAC in Study B (Table). Conclusions: Primary analysis of PFS favoring chemo with SOR versus PL in two phase IIb advanced BC trials was maintained after adjusting for imbalances. Overall survival data are pending. A large randomized phase III trial of CAP ± SOR is planned. Retained variables HR (95% CI) One-sided p value Study A Hormone status ER—/PR— vs. ER+ or PR+ 2.02 (1.38–2.96) 0.00015 Disease-free interval <2 y vs. 2 y+ 1.31 (0.92–1.87) 0.066 SOR vs. PL 0.64 (0.45–0.91) 0.006 Study B Hormone status ER—/PR— vs. ER+ or PR+ 1.73 (1.16–2.56) 0.003 Unknown vs ER+ or PR+ 1.58 (0.96–2.61) 0.04 Disease-free interval <1 y vs. 1 y+ 1.20 (0.85–1.71) 0.15 Age 50+ vs. <50 y 0.83 (0.58–1.17) 0.14 SOR vs. PL 0.73 (0.52–1.04) 0.04 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer, Onyx
Malnutrition and food habits; report of an international and interprofessional conference.
Authors: Anne. Burgess, R. F. A. Dean
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma
Authors: Jianhong Chu, Youcai Deng, Don M. Benson, Shun He, Tiffany L. Hughes, Jianying Zhang, Yong Peng, Hsiaoyin Mao, Ling Yi, Kalpana Ghoshal, Xiaoming He, Steven M. Devine, Xiaoliu Zhang, Michael A. Caligiuri, Craig C. Hofmeister, Jianhua Yu
Journal: Blood (2013)
Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interim analysis of a randomized German AIO phase II study
Authors: M. Moehler, S. Kanzler, M. Geissler, J. Raedle, M. Ebert, H. Scherubl, D. Flieger, T. Seufferlein, P. R. Galle, T. Hoehler
Journal: Journal of Clinical Oncology (2006)

4032 Background: Irinotecan with 5-FU is highly effective in advanced gastric cancer. In addition, capecitabine seems to be as effective as 5-FU, with its advantage of oral administration. Thus, we compared efficacy and toxicity of irinotecan/capecitabine versus cisplatin/capecitabine in this prospective multicentric, open trail. Methods: Patients (pts) with previously untreated locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction and Karnofsky Performance status (KPS) of ≥ 60%, at least one measurable lesion and adequate organ functions were eligible. Pts were randomized to 3-weekly cycles of irinotecan 250 mg/m 2 , day 1 (arm A) or to cisplatin 80 mg/m 2 , day 1 (arm B). Capecitabine was administered at a 1000 mg/m 2 twice daily for 14 days followed by a 7-day rest in both arms. Primary endpoint was remission rate, treatment was continued until disease progression. Results: At time of abstract submission, 91 of 120 pts (planned sample size) were randomized to arm A (45 pts) or B (46 pts). Interim data were available on 76 patients included into intent to treat analysis (34 pts arm A, 42 pts arm B). Baseline characteristics (arm A vs. B) were median age: 60 vs. 64 years, gender (female/male) 23%/77% vs. 30%/70%, KPS (≥80%) 97% vs. 93%, tumor distribution of gastric origin and gastroesophageal junction 85%/15% vs. 63%/37%. Grade 3 toxicities in A/B (% of pts) were anemia 3/9, neutropenia 17/19, diarrhoea 17/5, nausea 14/21, vomiting 3/14, hand-foot syndrome 6/2, respectively. Grade 4 toxicity occured only for neutropenia with 3% vs.5% in A/B, respectively. In 59 evaluable pts (28/31 in A/B), overall remission rate (CR + PR) and tumor control rate (CR + PR + SD) were 39% vs. 42% and 64% vs. 74%, respectively. Despite being only very descriptive, median progression-free and overall survival (arm A vs B) were 5.2 vs. 5.0 and 8.9 vs. 9.4 months, respectively. Conclusions: In patients with locally advanced or metastatic gastric and gastroesophageal cancer, both regimen irinotecan/capecitabine or cisplatin/capecitabine are effective, well tolerated and can be administered safely on an out-patient basis. Currently, both treatment arms are comparable. Accrual continues. No significant financial relationships to disclose.
Prospective assessment of short-term quality of life after total, distal or proximal gastrectomy for gastric cancer
Authors: D. Graham, E. Zucker, N. Ishmil, D. Coit, M. Brennan, M. Brennan
Journal: Journal of Clinical Oncology (2007)

15020 Background: Few studies have systematically examined the short-term quality of life (QOL) of patients undergoing gastrectomy for gastric cancer. This is due to a lack of consistent prospectively acquired baseline and early outcome measures. The purpose of the current study is to assess differences in QOL scores among patients within a year of curative distal (DG), proximal (PG) or total (TG) gastrectomy, using validated gastric cancer specific questionnaires. Methods: Patients undergoing curative gastrectomy were asked to prospectively complete preoperative, postoperative, 3, 6, and 12 month EORTC QLQ-C30 and STO22 questionnaires. We used analysis of covariance to compare differences in scores based on type of operation while adjusting for potential differences in baseline scores. Results: Patients undergoing DG (n=101), PG (n=20) or TG (n=49) were consented and interviewed. Data collection is complete on all patients through twelve months. In the immediate postoperative period, patients in all three surgical groups demonstrated worse scores in about half of the 23 function and symptom scales, compared to their preoperative scores. However, DG and TG patients had mostly returned to baseline by three to six months, while PG patients continued to remain below the baseline scores for many function and symptom scales over the entire twelve month period following surgery. PG patients had significantly poorer scores than DG and TG patients in reflux, nausea/vomiting, eating restrictions and anxiety scales, among others ( Table 1 ). Conclusion: This prospective study indicates that patients fared better after DG or TG than after PG in most function and symptom scales throughout the twelve month period following gastrectomy. Long term follow-up studies are required to see if these differences persist over time. Table 1 Mean change in score from preoperative baseline score (a negative value means return to baseline or better). [Table: see text] No significant financial relationships to disclose.
Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor
Authors: E. A. Donovan, Q. Ryan, M. Acharya, E. Chung, J. Trepel, K. Maynard, E. Sausville, A. Murgo, G. Melillo, B. Conley
Journal: Journal of Clinical Oncology (2005)

3094
Modern Trends in Psychological Medicine, 1948
Authors: Noel G. Harris
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Value of Cytogenetic Abnormalities in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Pediatric-Inspired Trials from the Group for Research on Adult ALL (GRAALL)
Authors: Marina Lafage-Pochitaloff, Laurence Baranger, Mathilde Hunault, Wendy Cuccuini, Audrey Bidet, Nicole Dastugue, Isabelle Tigaud, Catherine Henry, Carine Gervais, Dominique Penther, Christine Lefebvre, Nathalie Nadal, Francine Mugneret, Virginie Eclache, Isabelle Radford, Nathalie Gachard, Marie-Joelle Mozziconacci, Eric Delabesse, Marie C Bene, Agnès Chassevent, Kheira Beldjord, Vahid Asnafi, Françoise Huguet, Véronique Lhéritier, Norbert Ifrah, Hervé Dombret
Journal: Blood (2014)
Abstract 5936: Can Apoptosis Predict Functional Recovery in Acute Myocarditis?
Authors: Antonio Abbate, Gianfranco Sinagra, Rossana Bussani, Nicholas N Hoke, Stefano Toldo, Elena Barresi, Fadi N Salloum, Furio Silvestri, George W Vetrovec, Rakesh C Kukreja, Alfonso Baldi
Journal: Circulation (2008)

Background. Acute myocarditis is characterized by acute cardiac dysfunction followed by a variable recovery over time. Recent data have shown the presence of apoptosis in acute myocarditis. We hypothesized that the presence and extent of apoptosis evaluated at endomyocardial biopsy (EMB) could predict functional recovery in patients with acute myocarditis, with more apoptosis predicting less recovery. Methods. Sixteen patients with acute myocarditis were studied with EMB. Baseline and follow up echocardiography was obtained in all cases. The patients were retrospectively divided in 2 groups according to the final left ventricular ejection fraction (LVEF): LVEF&gt;40% [recovery] and LVEF≤40% [no recovery]. Co-staining for DNA fragmentation (TUNEL) and caspase-cleaved cytokeratin-18 (CytoDeath) were performed to quantify the cardiomyocyte apoptosis in EMB specimens. Four subjects dying of non-cardiac causes were selected as control hearts at time of autopsy. Results. Six patients showed functional recovery (38%) while 8 did not (62%). The apoptotic rate (AR, expressed as % of double positive cardiomyocytes on total number per field) was significantly higher in the hearts of patients with acute myocarditis (1.1%[0.7–2.2] vs 0.01%[0.01–0.01] in control hearts, p&lt;0.001). Unexpectedly, patients with functional recovery had a significantly higher AR than patients without recovery (3.2%[1.1–8.0] vs 0.5%[0.3–1.0], p=0.001), and the AR correlated with follow-up LVEF (R=+0.54, p=0.030). Six of the 8 patients (75%) with AR above average showed functional recovery vs 0 of the 8 patients (0%) with AR below average (p=0.007). Conclusions. This study surprisingly shows that the presence of greater apoptosis at EBM in patients with acute myocarditis predicts functional recovery at 12 months. Whether this represents a true cause-effect association or it simply represents a non-causal association remains unclear and warrants further studies.